# Immuneering (IMRX) — Analyst Forecast

IMRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imrx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 7 | 0 | 0 | 7 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 6, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $14.00 |
| Jul 20, 2026 | Needham | Maintained | Buy | $18.00 |
| Jul 8, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | — |
| May 19, 2026 | Chardan Capital | Maintained | Buy | $20.00 |
| Mar 9, 2026 | Needham | Maintained | Buy | $11.00 |
| Nov 13, 2025 | Chardan Capital | Maintained | Buy | $20.00 |
| Oct 31, 2025 | Leerink Partners | Initiated Coverage | Outperform | $15.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Maintained | Buy | $11.00 |
| Sep 26, 2025 | Chardan Capital | Maintained | Buy | $20.00 |
| Sep 25, 2025 | Oppenheimer | Maintained | Outperform | $30.00 |
| Sep 15, 2025 | Needham | Maintained | Buy | $11.00 |
| Aug 26, 2025 | Needham | Maintained | Buy | $8.00 |
| Aug 14, 2025 | Chardan Capital | Maintained | Buy | $13.00 |
| Jun 18, 2025 | Chardan Capital | Maintained | Buy | $13.00 |
| Jun 18, 2025 | Needham | Maintained | Buy | $9.00 |
| Jun 18, 2025 | Mizuho | Maintained | Outperform | $10.00 |
| Jun 5, 2025 | Needham | Maintained | Buy | $9.00 |
| May 7, 2025 | Oppenheimer | Maintained | Outperform | $21.00 |
| May 6, 2025 | Chardan Capital | Maintained | Buy | $13.00 |
| Apr 10, 2025 | Needham | Maintained | Buy | $12.00 |

## Frequently Asked Questions

### Is IMRX a buy, sell, or hold?

Analysts covering Immuneering currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on IMRX?

On Aug 6, 2026, HC Wainwright & Co. initiated coverage of Immuneering at Buy with a price target of $14.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).